By Ellen Capon (Drug Target Review)2023-11-13T14:00:59
Foxp3 alters chromatin architecture of regulatory T cells, meaning Foxp3 could become a target for therapies that modulate immunosuppression.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-03-20T13:41:33
Sponsored by Bio-Techne
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
Site powered by Webvision Cloud